Antibody company F-star Biotechnologische Forschungs und Entwicklungs GmbH (Vienna, Austria) hired John Haurum as CEO. Haurum is the former VP of research at ImClone Systems Inc. , which Eli Lilly and Co. (NYSE:LLY) acquired 2008. He...

F-star Biotechnologische Forschungs und Entwicklungs GmbH , Vienna, Austria   Business: Antibodies   Hired: Jane Dancer as COO, formerly VP of business development at Cellzome Ltd.; Sharon Grimster as VP of development, formerly a VP at...

FDA Commissioner Margaret Hamburg revoked accelerated approval of Oforta fludarabine from Sanofi as a second-line therapy to treat B cell chronic lymphocytic leukemia. According to the agency, Sanofi asked FDA to withdraw approval of Oforta,...

FDA Commissioner Margaret Hamburg revoked accelerated approval of Oforta fludarabine from Sanofi (Euronext:SAN; NYSE:SNY) as a second-line therapy to treat B cell chronic lymphocytic leukemia. According to the agency, Sanofi asked FDA to withdraw approval...

Summit Corp. plc (LSE:SUMM), Abingdon, U.K.   Business: Musculoskeletal, Endocrine/Metabolic, Infectious   Hired: Glyn Edwards as CEO and a director, formerly CEO of Antisoma plc  ...

The U.K. BioIndustry Association said CEO Nigel Gaymond left to pursue other opportunities. Glyn Edwards will become interim CEO. Edwards was CEO of cancer company Antisoma plc (LSE:ASM)....

Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway   Business: Drug delivery, Cancer, Infectious   Hired: Nicholas Adams as CBO, formerly VP of business development at Antisoma plc ; he replaces Jan Alfheim, who is departing to...

e-Therapeutics Ltd. (LSE:ETX), Newcastle, U.K.   Business: Infectious, Cancer   Hired: Daniel Elger as CFO and a director, formerly VP of marketing and communications at Antisoma plc   Departed: J.M. Cordiner as finance director  ...

GenKyoTex S.A. , Geneva, Switzerland   Business: Pulmonary, Renal, Cardiovascular   Hired: Ursula Ney as CEO and executive director, formerly COO at Antisoma plc  ...

The European biotech industry is now about a generation old - long enough for investors and managements to benefit from the experiences of several business cycles. While it is easy to complain about the flaws in...